P2X Purinergic Receptor Neurons

📖 Wiki Page

cell2412 wordssynced 2026-04-02

P2X Purinergic Receptor Neurons

Introduction

...

P2X Purinergic Receptor Neurons

Introduction

<table class="infobox infobox-cell">
<tr>
<th class="infobox-header" colspan="2">P2X Purinergic Receptor Neurons</th>
</tr>
<tr>
<td class="label">Receptor</td>
<td>Distribution</td>
</tr>
<tr>
<td class="label">P2X1</td>
<td>DRG, smooth muscle</td>
</tr>
<tr>
<td class="label">P2X2</td>
<td>CNS, autonomic</td>
</tr>
<tr>
<td class="label">P2X3</td>
<td>DRG,nociceptors</td>
</tr>
<tr>
<td class="label">P2X4</td>
<td>CNS, microglia</td>
</tr>
<tr>
<td class="label">P2X5</td>
<td>Spinal cord</td>
</tr>
<tr>
<td class="label">P2X6</td>
<td>CNS</td>
</tr>
<tr>
<td class="label">P2X7</td>
<td>Immune cells, glia</td>
</tr>
<tr>
<td class="label">Target</td>
<td>Drug</td>
</tr>
<tr>
<td class="label">P2X3</td>
<td>gefaprixant</td>
</tr>
<tr>
<td class="label">P2X3</td>
<td>Blu-4702</td>
</tr>
<tr>
<td class="label">P2X7</td>
<td>CE-224545</td>
</tr>
<tr>
<td class="label">Mechanism</td>
<td>P2X Involved</td>
</tr>
<tr>
<td class="label">Amyloid-β interaction</td>
<td>P2X4, P2X7</td>
</tr>
<tr>
<td class="label">Calcium dysregulation</td>
<td>All subtypes</td>
</tr>
<tr>
<td class="label">Neuroinflammation</td>
<td>P2X7</td>
</tr>
<tr>
<td class="label">Memory impairment</td>
<td>P2X2, P2X4</td>
</tr>
<tr>
<td class="label">Finding</td>
<td>Mechanism</td>
</tr>
<tr>
<td class="label">Elevated P2X7</td>
<td>Inflammation</td>
</tr>
<tr>
<td class="label">Reduced P2X2</td>
<td>Synaptic dysfunction</td>
</tr>
<tr>
<td class="label">Altered P2X4</td>
<td>Microglial activation</td>
</tr>
<tr>
<td class="label">Receptor</td>
<td>Location</td>
</tr>
<tr>
<td class="label">P2X3</td>
<td>DRG, nociceptors</td>
</tr>
<tr>
<td class="label">P2X2/3</td>
<td>DRG, interneurons</td>
</tr>
<tr>
<td class="label">P2X4</td>
<td>Dorsal horn</td>
</tr>
<tr>
<td class="label">P2X7</td>
<td>Immune cells</td>
</tr>
<tr>
<td class="label">Drug</td>
<td>Target</td>
</tr>
<tr>
<td class="label">Gefaprixant</td>
<td>P2X3</td>
</tr>
<tr>
<td class="label">Blu-4702</td>
<td>P2X3</td>
</tr>
<tr>
<td class="label">CE-224545</td>
<td>P2X7</td>
</tr>
<tr>
<td class="label">JNJ-54179060</td>
<td>P2X7</td>
</tr>
<tr>
<td class="label">JNJ-42253452</td>
<td>P2X3</td>
</tr>
<tr>
<td class="label">Challenge</td>
<td>Approach</td>
</tr>
<tr>
<td class="label">CNS penetration</td>
<td>Lipophilicity</td>
</tr>
<tr>
<td class="label">Selectivity</td>
<td>Structure-based design</td>
</tr>
<tr>
<td class="label">Chronic dosing</td>
<td>Slow-release formulations</td>
</tr>
<tr>
<td class="label">Side effects</td>
<td>Tissue-selective targeting</td>
</tr>
<tr>
<td class="label">Model</td>
<td>Application</td>
</tr>
<tr>
<td class="label">Xenopus oocytes</td>
<td>Electrophysiology</td>
</tr>
<tr>
<td class="label">HEK293 cells</td>
<td>Pharmacology</td>
</tr>
<tr>
<td class="label">Primary neurons</td>
<td>CNS studies</td>
</tr>
<tr>
<td class="label">DRG cultures</td>
<td>Pain research</td>
</tr>
<tr>
<td class="label">Marker</td>
<td>Sample</td>
</tr>
<tr>
<td class="label">P2X7</td>
<td>CSF</td>
</tr>
<tr>
<td class="label">P2X4</td>
<td>Blood</td>
</tr>
<tr>
<td class="label">ATP release</td>
<td>Microdialysis</td>
</tr>
<tr>
<td class="label">Agonist</td>
<td>Selectivity</td>
</tr>
<tr>
<td class="label">α,β-MeATP</td>
<td>P2X1, P2X3</td>
</tr>
<tr>
<td class="label">BzATP</td>
<td>P2X7</td>
</tr>
<tr>
<td class="label">ATP</td>
<td>Pan-P2X</td>
</tr>
<tr>
<td class="label">Antagonist</td>
<td>Selectivity</td>
</tr>
<tr>
<td class="label">TNP-ATP</td>
<td>P2X1-3</td>
</tr>
<tr>
<td class="label">A-438079</td>
<td>P2X7</td>
</tr>
<tr>
<td class="label">suramin</td>
<td>Pan-P2X</td>
</tr>
<tr>
<td class="label">BBG</td>
<td>P2X7</td>
</tr>
<tr>
<td class="label">Biomarker</td>
<td>Selection Criteria</td>
</tr>
<tr>
<td class="label">P2X7 expression</td>
<td>Elevated in disease</td>
</tr>
<tr>
<td class="label">Pain threshold</td>
<td>P2X3 involvement</td>
</tr>
<tr>
<td class="label">Inflammation</td>
<td>P2X7 activation</td>
</tr>
<tr>
<td class="label">Co-medications</td>
<td>Interaction</td>
</tr>
<tr>
<td class="label">Opioids</td>
<td>Additive analgesia</td>
</tr>
<tr>
<td class="label">NSAIDs</td>
<td>Anti-inflammatory</td>
</tr>
<tr>
<td class="label">Gabapentinoids</td>
<td>Synergistic</td>
</tr>
<tr>
<td class="label">Drug</td>
<td>Target</td>
</tr>
<tr>
<td class="label">Gefaprixant</td>
<td>P2X3</td>
</tr>
<tr>
<td class="label">Blu-4702</td>
<td>P2X3</td>
</tr>
<tr>
<td class="label">JNJ-54179060</td>
<td>P2X7</td>
</tr>
<tr>
<td class="label">JNJ-42253452</td>
<td>P2X3</td>
</tr>
<tr>
<td class="label">AZD-1236</td>
<td>P2X7</td>
</tr>
<tr>
<td class="label">Endpoint</td>
<td>Measure</td>
</tr>
<tr>
<td class="label">Pain reduction</td>
<td>VAS score</td>
</tr>
<tr>
<td class="label">Cough frequency</td>
<td>Episodes/day</td>
</tr>
<tr>
<td class="label">Cognition</td>
<td>MMSE</td>
</tr>
<tr>
<td class="label">Inflammation</td>
<td>Cytokines</td>
</tr>
<tr>
<td class="label">P2X</td>
<td>Primary Pathway</td>
</tr>
<tr>
<td class="label">P2X3</td>
<td>Ca2+ influx</td>
</tr>
<tr>
<td class="label">P2X4</td>
<td>Ca2+ release</td>
</tr>
<tr>
<td class="label">P2X7</td>
<td>Pore formation</td>
</tr>
<tr>
<td class="label">Parameter</td>
<td>Value</td>
</tr>
<tr>
<td class="label">Oral bioavailability</td>
<td>30-60%</td>
</tr>
<tr>
<td class="label">Cmax</td>
<td>2-4 hours</td>
</tr>
<tr>
<td class="label">Half-life</td>
<td>4-8 hours</td>
</tr>
<tr>
<td class="label">Tmax</td>
<td>2-4 hours</td>
</tr>
<tr>
<td class="label">Compartment</td>
<td>Notes</td>
</tr>
<tr>
<td class="label">Brain penetration</td>
<td>Limited for most</td>
</tr>
<tr>
<td class="label">CSF levels</td>
<td>1-5% of plasma</td>
</tr>
<tr>
<td class="label">Protein binding</td>
<td>60-80%</td>
</tr>
<tr>
<td class="label">Effect</td>
<td>Incidence</td>
</tr>
<tr>
<td class="label">Headache</td>
<td>10-15%</td>
</tr>
<tr>
<td class="label">Nausea</td>
<td>5-10%</td>
</tr>
<tr>
<td class="label">GI upset</td>
<td>5-10%</td>
</tr>
<tr>
<td class="label">ATP sensitivity (nM)</td>
<td>100</td>
</tr>
<tr>
<td class="label">Desensitization</td>
<td>Slow</td>
</tr>
<tr>
<td class="label">Ca2+ permeability</td>
<td>+++</td>
</tr>
<tr>
<td class="label">Distribution</td>
<td>PNS</td>
</tr>
<tr>
<td class="label">Target</td>
<td>Efficacy</td>
</tr>
<tr>
<td class="label">P2X3</td>
<td>High</td>
</tr>
<tr>
<td class="label">P2X4</td>
<td>Moderate</td>
</tr>
<tr>
<td class="label">P2X7</td>
<td>High</td>
</tr>
<tr>
<td class="label">Cell Type</td>
<td>P2X</td>
</tr>
<tr>
<td class="label">Astrocyte</td>
<td>P2X7</td>
</tr>
<tr>
<td class="label">Microglia</td>
<td>P2X4, P2X7</td>
</tr>
<tr>
<td class="label">Oligodendrocyte</td>
<td>P2X7</td>
</tr>
<tr>
<td class="label">Marker</td>
<td>Sample</td>
</tr>
<tr>
<td class="label">P2X7</td>
<td>CSF</td>
</tr>
<tr>
<td class="label">P2X4</td>
<td>Blood</td>
</tr>
<tr>
<td class="label">ATP</td>
<td>Microdialysis</td>
</tr>
<tr>
<td class="label">P2X7 autoantibody</td>
<td>Serum</td>
</tr>
</table>

P2X Purinergic Receptor Neurons are neurons that express P2X receptors, a family of ATP-gated ion channels that play crucial roles in fast synaptic transmission, pain sensing, and neurodegenerative processes. These receptor neurons are widely distributed throughout the central and peripheral nervous systems and represent important therapeutic targets for neurological disorders[@burnstock2008].

Overview

P2X receptors are cationic channels activated by extracellular adenosine triphosphate (ATP). Seven subtypes (P2X1-P2X7) have been identified, each with distinct pharmacological properties and anatomical distributions. P2X receptors mediate rapid responses to synaptic ATP release, making them critical for neural communication.

Mermaid diagram (expand to render)

Receptor Properties

P2X Receptor Subtypes

Signaling Mechanisms

P2X receptors are ATP-gated ion channels that permit Na+ and Ca2+ influx upon activation. The signaling cascade involves[@neary2005]:

ATP release: From presynaptic terminals or pathologically damaged cells

Receptor activation: ATP binds to P2X receptor extracellular domain

Ion channel opening: Conformational change allows cation influx

Depolarization: Fast excitatory postsynaptic potentials

Calcium signaling: Activation of intracellular calcium-dependent pathways

Role in Neurodegeneration

Excitotoxicity

P2X receptor overactivation contributes to excitotoxic cell death[@abbracchio2009]:

Mermaid diagram (expand to render)

Disease Associations

Amyotrophic Lateral Sclerosis (ALS)

P2X7 receptor expression is elevated in ALS:

Contributes to motor neuron excitotoxicity
Mediates microglial activation
Target for therapeutic intervention

Parkinson's Disease

P2X7 in dopaminergic neuron death
Neuroinflammation modulation
Potential biomarker

Alzheimer's Disease

Amyloid-beta interaction with P2X receptors
Calcium dysregulation enhancement
Synaptic dysfunction contribution

Pain Signaling

P2X receptors are critical for nociception, particularly P2X3 and P2X2/3[@ralevic2018].

Nociceptive Pathways

Mermaid diagram (expand to render)

Therapeutic Targeting

Therapeutic Implications

Drug Development

P2X receptors are validated drug targets:

Antagonists: Block excessive activation

Allosteric modulators: Fine-tune receptor activity

agonists: Enhance protective signaling

CNS Disorders

Chronic pain: P2X3, P2X2/3 antagonists
Neurodegeneration: P2X7 antagonists
Mood disorders: P2X7 modulation

Cell-Type Specific Expression

Primary Sensory Neurons

DRG neurons: P2X3, P2X2/3
Nociceptors: P2X3 dominant
Thermoreceptors:Mixed subtypes

Central Neurons

Cortical neurons: P2X2, P2X4
spinal cord neurons: P2X2, P2X5
Hypothalamic neurons: P2X6

Glia

Microglia: P2X7 dominant
Astrocytes: P2X4 expression

Disease Mechanisms

Parkinson's Disease

P2X receptors play complex roles in PD pathogenesis[@chen2012]:

Dopaminergic Neuron Vulnerability

P2X7 activation in substantia nigra
Enhanced excitotoxicity
Microglial activation
Progressive degeneration

Neuroinflammation

Chronic microglial activation
Cytokine release (IL-1β, TNF-α)
Progressive neuroinflammation
Neuronal loss amplification

Therapeutic Potential

P2X7 antagonists: Neuroprotection
P2X4 modulators: Anti-inflammatory
Combination approaches

Mermaid diagram (expand to render)

Alzheimer's Disease

In AD, P2X receptors contribute to pathology[@joseph2013]:

Amyloid-beta Interaction

Direct activation of P2X receptors
Enhanced calcium influx
Synaptic dysfunction
Memory impairment

Therapeutic Targeting

P2X7 antagonists: Reduce neuroinflammation
P2X4 modulators: Protect synapses
P2X2/4 agonists: Enhance cognition

Biomarker Potential

CSF P2X7 levels: Disease monitoring
Peripheral blood markers: Screening

Amyotrophic Lateral Sclerosis

P2X receptors are involved in ALS:

Motor Neuron Degeneration

P2X7 upregulation in motor neurons
Excitotoxic cell death
Impaired glutamate clearance

Microglial Contributions

Chronic activation via P2X7
Pro-inflammatory cytokine release
Non-cell autonomous degeneration

Therapeutic Approaches

P2X7 antagonists in development
Gene therapy approaches
Combined neuroprotection

Multiple Sclerosis

In demyelinating diseases:

Oligodendrocyte Vulnerability

P2X7-mediated death
Myelin breakdown
Axonal injury

Therapeutic Potential

P2X7 blockade: Neuroprotection
Remyelination promotion

Psychiatric Disorders

P2X receptors are emerging targets in psychiatry[@wu2019]:

Depression

Monoamine Interaction

P2X7 in serotonin release
Dopamine modulation
Mood regulation

Inflammatory Link

Cytokine-induced P2X7 activation
Depression behavior
Treatment resistance

Clinical Trials

P2X7 antagonists in Phase 2
Treatment-resistant depression
Bipolar depression

Anxiety

P2X receptors in anxiety:

P2X7: Anxiogenic effects
P2X4: Anxiolytic potential
Receptor-selective targeting

Schizophrenia

Findings in schizophrenia[@suarez2019]:

P2X7 polymorphisms associated
P2X4 expression changes
Cognitive deficits link

Epilepsy

P2X receptors in seizure disorders[@frank2014]:

Mechanisms

Seizure Initiation

ATP release during seizures
P2X receptor activation
Hyperexcitability

ictal Spread

Network synchronization
Activity propagation

Therapeutic Targeting

P2X antagonists: Anticonvulsant
P2X2/3: Modulation

Status Epilepticus

In prolonged seizures:

P2X7-mediated neurodegeneration
Therapeutic intervention potential

Pain Signaling Mechanisms

Nociception

P2X3 and P2X2/3 are primary pain receptors[@muller2018]:

Neuropathic Pain

P2X4 underlies neuropathic pain[@barber2014]:

Microglial P2X4 Activation

Spinal cord microglia
BDNF release
Neuronal dysregulation

Pain Transmission

Enhanced excitability
Central sensitization

Therapeutic Approaches

P2X4 antagonists
Microglial inhibition

Inflammatory Pain

P2X7 in inflammatory pain:

Cytokine release
Hyperalgesia
Therapeutic targeting

Drug Development

Clinical Candidates

Challenges

Future Directions

Subtype-Selective Drugs

P2X3 antagonists
P2X4 modulators
P2X7 allosteric modulators

Combination Therapies

P2X + opioid
P2X + gabapentinoid
Receptor-selective approaches

Research Models

In Vitro Models

In Vivo Models

Knockout mice: P2X7-/-, P2X3-/-
Transgenic: overexpression
Conditional: cell-type specific

Biomarkers

Pharmacological Properties

Agonists

Antagonists

Structure-Activity

Key structural features for antagonism:

Hydrophobic core
Polar head groups
Hydrogen bonding
Receptor subtypes selectivity

Clinical Considerations

Patient Selection

Monitoring

Efficacy: Pain scores, inflammation markers
Safety: Liver function, blood counts
Biomarkers: ATP levels, receptor expression

Drug Interactions

References

[Burnstock et al., Purinergic signalling (2008)](https://doi.org/10.1016/j.expneurol.2007.03.007)

[Neary et al., P2 receptor signaling in neurodegeneration (2005)](https://doi.org/10.1016/j.tips.2005.04.003)

[Abbracchio et al., Purinergic signaling in brain disease (2009)](https://doi.org/10.1038/nrn2485)

[Ralevic et al., P2X receptors as pain targets (2018)](https://doi.org/10.1016/j.pharmthera.2017.11.001)

[Khmyz et al., P2X7 receptor in neuroinflammation (2010)](https://doi.org/10.1186/1742-2094-7-49)

[Barber et al., P2X4 receptors in neuropathic pain (2014)](https://doi.org/10.1097/01.j.pain.0000449878.31785.1c)

[Facchin et al., P2X receptors in cognitive disorders (2014)](https://doi.org/10.3389/fncel.2014.00225)

[Muller et al., P2X3 antagonists for chronic pain (2018)](https://doi.org/10.1016/j.ejphar.2018.03.012)

[Chen et al., Purinergic signaling in Parkinson's (2012)](https://doi.org/10.1016/j.pneurobio.2012.03.001)

[Joseph et al., P2X receptors in Alzheimer's (2013)](https://doi.org/10.1111/acel.12088)

[Wu et al., ATP-gated ion channels in depression (2019)](https://doi.org/10.1038/s41380-018-0209-0)

[Suarez et al., P2X7 in psychiatric disorders (2019)](https://doi.org/10.1038/s41386-019-0445-1)

Therapeutic Implications and Drug Development

Drug Development Pipeline

Current P2X receptor-targeted drugs in development:

Mechanisms of Drug Action

P2X3 Antagonists

Block ATP-mediated pain signaling
Reduce peripheral sensitization
Decrease CNS hyperexcitability

P2X7 Antagonists

Inhibit microglial activation
Reduce cytokine release
Protect neurons from excitotoxicity

P2X4 Modulators

Balance microglial function
Reduce neuropathic pain
Improve cognitive function

Clinical Trial endpoints

Molecular Pharmacology

Receptor Structure

P2X receptors are trimeric ion channels:

Subunit Structure

Two transmembrane domains
Extracellular ATP-binding domain
Intracellular N- and C-termini

Channel Properties

Permable to Na+, K+, Ca2+
Rapid desensitization (P2X3)
Sustained activation (P2X7)

ATP-Binding Site

Conformational changes
Channel opening
Ion flux regulation

Signaling Cascades

Pharmacokinetics

Absorption

Distribution

Metabolism and Elimination

Metabolism: Liver (CYP450)
Excretion: Renal (60-80%)
Active metabolites: Some

Adverse Effects

Common Side Effects

Serious Concerns

Liver toxicity: Monitor function
Immunosuppression: Infection risk
Bleeding: Platelet function

Contraindications

Pregnancy: Insufficient data
Liver disease: Avoid
Severe renal disease: Caution

Comparative Pharmacology

P2X Receptor Subtype Selectivity

Therapeutic Index

Neurobiology

Synaptic Transmission

P2X receptors in synaptic function:

Fast Synaptic Transmission

ATP as co-transmitter
Rapid postsynaptic responses
Receptor recycling

Modulatory Effects

Presynaptic modulation
Activity-dependent release
Plasticity mechanisms

Network Activity

Oscillation regulation
Rhythm generation
Information processing

Glial-Neuronal Communication

P2X receptors mediate glia-neuron signaling:

Biomarkers and Diagnostics

Clinical Biomarkers

Diagnostic Applications

Disease Staging

P2X7 expression levels
ATP release capacity
Receptor function

Treatment Response

Drug efficacy markers
Target engagement
Side effect prediction

Prognostic value

Disease progression
Treatment response
Survival indicators

P2X Purinergic Receptor Neurons

P2X Purinergic Receptor Neurons

Introduction

P2X Purinergic Receptor Neurons

Introduction

Overview

Receptor Properties

P2X Receptor Subtypes

Signaling Mechanisms

Role in Neurodegeneration

Excitotoxicity

Disease Associations

Amyotrophic Lateral Sclerosis (ALS)

Parkinson's Disease

Alzheimer's Disease

Pain Signaling

Nociceptive Pathways

Therapeutic Targeting

Therapeutic Implications

Drug Development

CNS Disorders

Cell-Type Specific Expression

Primary Sensory Neurons

Central Neurons

Glia

Disease Mechanisms

Parkinson's Disease

Alzheimer's Disease

Amyotrophic Lateral Sclerosis

Multiple Sclerosis

Psychiatric Disorders

Depression

Anxiety

Schizophrenia

Epilepsy

Mechanisms

Status Epilepticus

Pain Signaling Mechanisms

Nociception

Neuropathic Pain

Inflammatory Pain

Drug Development

Clinical Candidates

Challenges

Future Directions

Research Models

In Vitro Models

In Vivo Models

Biomarkers

Pharmacological Properties

Agonists

Antagonists

Structure-Activity

Clinical Considerations

Patient Selection

Monitoring

Drug Interactions

See Also

References

Therapeutic Implications and Drug Development

Drug Development Pipeline

Mechanisms of Drug Action

Clinical Trial endpoints

Molecular Pharmacology

Receptor Structure

Signaling Cascades

Pharmacokinetics

Absorption

Distribution

Metabolism and Elimination

Adverse Effects

Common Side Effects

Serious Concerns

Contraindications

Comparative Pharmacology

P2X Receptor Subtype Selectivity

Therapeutic Index

Neurobiology

Synaptic Transmission

Glial-Neuronal Communication